Maxpil

Finasteride, the active ingredient in Maxpil, is a 5-alpha-reductase inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of male pattern hair loss and benign prostatic hyperplasia in adult males. GNH USA supplies Maxpil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Finasteride acts on the androgen pathway to address conditions driven by dihydrotestosterone. - Male pattern hair loss (androgenetic alopecia): reduces hair shedding and promotes regrowth in men. - Benign prostatic hyperplasia (BPH): improves urinary flow and decreases prostate volume in affected patients.

Finasteride may cause a range of adverse reactions.

Common Side Effects: - Decreased libido: reduced sexual desire in some men. - Erectile dysfunction: difficulty achieving or maintaining an erection. - Ejaculation disorder: altered volume or force of ejaculation. - Breast tenderness or enlargement: mild discomfort or tissue growth.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Breast cancer: rare reports of malignant breast tissue development. - Severe depression or mood changes: significant psychological effects that may need urgent care.

Finasteride requires careful consideration of several safety factors. - Pregnancy: contraindicated (Category X) – avoid use in women who are or may become pregnant. - Breastfeeding: not recommended – finasteride may be excreted in milk. - Age: indicated for adult males only – not studied in children or adolescents. - Drug interactions: review concomitant medications, especially strong CYP3A4 inhibitors. - Medical conditions: use with caution in patients with hepatic impairment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Finasteride can interact with other medicines, requiring monitoring or avoidance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase finasteride plasma levels. - Co‑administration with other 5‑alpha‑reductase inhibitors: additive hormonal effects.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., tamsulosin): may cause additive hypotensive effects. - Hormonal therapies (e.g., testosterone): may alter finasteride efficacy. - Warfarin: monitor INR as finasteride may affect anticoagulation control.